17 March 2026 | News
Image Courtesy: Public Domain
Vicarious Surgical Inc. (OTCID: RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery, announced a series of strategic actions intended to strengthen the Company’s financial position, enhance trading liquidity, and support a potential relisting of its common stock on a national exchange.
Over the past several months, Vicarious Surgical has implemented significant operational and cost discipline initiatives designed to align the Company’s expense structure with its current stage of development while maintaining progress toward key technology milestones.
As a result of these initiatives, the Company expects full-year 2026 cash burn of approximately $19 million, a substantial reduction from the approximately $35 million burn guidance provided in late 2025. In mid-2025, the Company’s annual cash burn was approximately $50 million due to its operating structure. These changes reflect a significant structural improvement in the Company’s cost profile, including increased use of outsourcing and operational efficiencies, while preserving progress toward key development milestones.
The Company’s strategic cost discipline has not slowed momentum in the development of the Vicarious Surgical System. Vicarious Surgical remains on track to achieve system design freeze by the end of 2026, a critical milestone in the Company’s regulatory and commercialization roadmap.
Based on its current operating plan, the Company believes that its existing cash resources provide runway through the second quarter of 2026, allowing the Company to pursue its capital markets strategy.
Capital Markets Strategy
As part of its broader strategy to strengthen the Company’s capital markets profile, Vicarious Surgical has submitted an application to list its Class A common stock on the Nasdaq Capital Market.
In connection with this initiative, the Company has filed a preliminary proxy statement with the Securities and Exchange Commission seeking stockholder approval to authorize the Company’s Board of Directors to implement a reverse stock split of the Company’s common stock at a ratio to be determined by the Board. The reverse stock split is intended to enable the Company’s shares to meet Nasdaq’s minimum bid price requirement for listing.
Vicarious Surgical is exploring capital raising strategies to support continued development of the Vicarious Surgical System and assist the Company in satisfying applicable Nasdaq initial listing requirements.
There can be no assurance that the Company will be able to satisfy Nasdaq’s listing standards or complete any proposed capital raising alternative.
OTCQB Application and Trading Liquidity
Following the Company’s recent transition from the New York Stock Exchange, its common stock began trading on the OTCID market tier. The Company has submitted an application to upgrade its quotation to the OTCQB Venture Market, which is designed for early-stage and developing companies.
The Company believes that trading on the OTCQB Venture Market would improve market visibility and facilitate greater market maker participation, which may enhance trading liquidity while the Company pursues its potential relisting on a national exchange.
Management Commentary
“Over the past several months, we have taken decisive steps to streamline our operating structure and significantly reduce our cash burn while maintaining our core development timeline,” said Stephen From, Chief Executive Officer of Vicarious Surgical.
“These actions position us with a more capital-efficient operating model while we continue advancing toward system design freeze by year-end. At the same time, we are actively pursuing a path back to a national exchange through our Nasdaq listing application. We believe these steps strengthen our foundation and support our long-term objective of bringing our robotic surgical platform to market.”
